Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.0552W HIGH $21.24
Volume
793.93 K
Value Traded
18.63 M
Short % Float
18.03%
+4.92%Week
+6.67%1 Month
+98.1%3 Month
+74.25%6 Month
-24.9%5 Year
+30.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.44 B
EPS (TTM)
0.52
P/E Ratio
38.24
Ent. Value
1.30 B
Total Shares
72.35 M
Float Shares
69.29 M
Insiders
4.29%
Institutions
49.92%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
OMER Catalyst Timeline
Dated clinical, regulatory and corporate events for Omeros Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Omeros Corporation
444Total events
9Upcoming
110Tier-1 (high impact)
2009 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Other Regulator MilestoneYARTEMLEAApprovedEx-US Regulatory
CMS grants NTAP status to YARTEMLEA under FY 2027 IPPS Final Rule
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲Other Regulator MilestoneYARTEMLEAApprovedEx-US Regulatory
CMS assigns permanent HCPCS J-code J1289 for YARTEMLEA
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲Reimbursement / PricingYARTEMLEAApprovedPost-Market
Permanent HCPCS J-code specific for YARTEMLEA became effective
stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲Debt Royalty FinancingCorporate
Completed repurchase of $30.5 million aggregate principal amount of 2029 Notes
▲Equity OfferingCorporate
Repurchased and retired approximately 0.5 million and 0.8 million shares of common stock
●EU MAA SubmissionnarsoplimabApprovedEx-US Regulatory
European Marketing Authorization Application for narsoplimab in TA-TMA
transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲PublicationPresentation
First peer-reviewed manuscript describing T-CAT technology published in Science Translational Medicine
◆EU MAA SubmissionYARTEMLEAApprovedEx-US Regulatory
MAA for YARTEMLEA under review by EMA
TA-TMAsource ↗
▼CHMP Negative OpinionnarsoplimabApprovedEx-US Regulatory
CHMP adopted negative opinion on MAA for narsoplimab in TA-TMA
stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲Product LaunchYARTEMLEAApprovedPost-Market
CMS assigns permanent reimbursement J-code for YARTEMLEA
◆EU MAA SubmissionYARTEMLEAApprovedEx-US Regulatory
Marketing authorization application for YARTEMLEA under review at EMA
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
●Oral PresentationPresentation
Industry session at EBMT 2026 on advances in TA-TMA treatment
TA-TMAsource ↗
▲Preclinical PoCOncotoX-AMLPreclinical
Successful nonhuman primate study demonstrating efficacy and safety
acute myeloid leukemia (AML)source ↗
●IND Enabling CompleteOncotoX-AMLPreclinical
Initiating IND-enabling studies
acute myeloid leukemia (AML)source ↗
▲Preclinical PoCOncotoX-AMLPreclinical
Completed initial nonhuman primate study for OncotoX-AML
AMLsource ↗
▲Product LaunchYARTEMLEAApprovedPost-Market
First commercial sales of YARTEMLEA in the U.S.
stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲Product LaunchYARTEMLEAApprovedPost-Market
First commercial shipments of YARTEMLEA completed
stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲Product LaunchYARTEMLEAApprovedPost-Market
U.S. market launch of YARTEMLEA
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲Product LaunchYARTEMLEAApprovedPost-Market
Commercial distribution and sales of YARTEMLEA began
TA-TMAsource ↗
▲FDA ApprovalYARTEMLEAApprovedFDA Decision
FDA approval of YARTEMLEA for TA-TMA
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲FDA ApprovalYARTEMLEAApprovedFDA Decision
FDA approval of YARTEMLEA for TA-TMA
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲Partnership / LicensezaltenibartCorporate
Closing of asset purchase and license agreement with Novo Nordisk for zaltenibart
paroxysmal nocturnal hemoglobinuria (PNH), renal diseases such as immunoglobulin A nephropathy (IgAN), C3 glomerulopathy and atypical hemolytic uremic syndrome, and other immune and complement-driven disorderssource ↗
▲Milestone PaymentzaltenibartCorporate
Upfront and near-term milestone payments up to $340M, with $240M upfront paid at closing
▲Debt Royalty FinancingCorporate
Prepaid $67.1M senior secured term loan, terminating credit agreement and releasing liens
▲Runway Guidance UpdateCorporate
Remaining proceeds expected to fund >12 months of operations including narsoplimab launch and repay $17.1M convertible notes
▲Partnership / LicensezaltenibartCorporate
Closed transaction with Novo Nordisk for zaltenibart
▲Equity OfferingCorporate
Repayment of $67.1M senior secured credit agreement and $17.1M convertible notes
▲FDA ApprovalYARTEMLEAApprovedFDA Decision
FDA approval of YARTEMLEA (narsoplimab-wuug) for TA-TMA
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and oldersource ↗
▲Product LaunchYARTEMLEAApprovedPost-Market
Commercial launch of YARTEMLEA in the U.S.
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
▲Partnership / LicensezaltenibartCorporate
Asset purchase and licensing agreement with Novo Nordisk for zaltenibart (formerly OMS906)
PNH and other alternative pathway indicationssource ↗
●Development Candidate NominationOncotoX-AMLPreclinical
Completed selection of drug development candidate for OncotoX-AML
acute myeloid leukemia (AML)source ↗
◆BLA SubmissionnarsoplimabApprovedRegulatory Filing
Targeting mid-2024 FDA decision for narsoplimab BLA resubmission for TA-TMA
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)source ↗
◆Trial InitiationOMS1029Trial
OMS1029 Phase 2 program slated to begin next summer
complement-mediated diseasessource ↗
◆Topline ReadoutnarsoplimabApprovedClinical Data
Topline data from pivotal ARTEMIS-IGAN trial expected in Q3 2023
IgA nephropathy (IgAN)source ↗
◆FDA Feedback ReceivednarsoplimabApprovedFDA Meeting
Meeting with FDA this month to discuss BLA resubmission for TA-TMA
TA-TMAsource ↗
Past FDA Catalysts and PDUFA Decisions
How OMER actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-29 | Narsoplimab (MASP-2 inhibitor) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$74M
Pipeline Value
$91M
Commercial Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 52%
Micro Cap(rank 344 of 660)
Percentile Rank
Omeros Corporation faces pipeline headwinds (36/100), with $185M risk-adjusted pipeline value, led by OMS906 in Paroxysmal Nocturnal Hemoglobinuria (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $38.4M x 2.4 = $91M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| YARTEMLEA | $38M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OMS906 Small moleculeNCT06298955 | Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | ACTIVE NOT_RECRUITING | 52 | Apr 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every OMER program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OMS906 | treatment-naive PNH patients | 2023-05-09 | Both Hgb and LDH improvements are statistically significant at all time points in the trial; OMS906 has been well tolerated and there have been no safety signals of concern.Read More | Omeros Corporation Reports First Quarter 2023 Financial Results - Conference Call Today at 4:30 p.m. ET - SEATTLE, WARead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Borges David J.Officer (VP, Finance & CAO) | Option | 10,000 10,000 held | $15.58 | 09/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OMER
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0.6 % (50 %) | 13.42 M | 1.41 M | 24.46% ( 277.40 K) |
OMER Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-05-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OMER ranks across every disease it competes in
Competitive Position is a premium feature
See how OMER ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOMER News
OMER▲ +26.5%on this news
Omeros Corporation Reports Second Quarter 2026 Financial Results
Omeros Corporation reported its financial results for the second quarter of 2026, highlighting significant revenue from YARTEMLEA®, the first approved treatment for TA-TMA. The treatment generated $32.2 million in gross revenues during this period, indicating strong market performance. The company continues to advance its position in the biopharmaceutical sector.
Read more →OMEROmeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Omeros Corporation will release its financial results for Q2 2026 on August 12, 2026, after market close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss the results and recent developments. This event highlights Omeros' commitment to keeping stakeholders informed.
Read more →OMER▲ +6.1%on this news
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
Omeros Corporation announced that the CMS has granted New Technology Add-On Payment status to YARTEMLEA (narsoplimab-wuug) for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplants. This status will take effect on October 1, 2026, allowing eligible hospitals to receive additional payments for treating Medicare patients with this therapy.
Read more →OMER▼ -19.1%on this news
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
Omeros Corporation has provided an update regarding its European Marketing Authorization Application for narsoplimab, a treatment for TA-TMA. The details of the update have not been disclosed in the article. The company continues to pursue regulatory approval in Europe for this indication.
Read more →OMER▲ +6.8%on this news· ran to +18% by day 3
Omeros Announces Webcast Details for Annual Meeting of Shareholders
Omeros has announced the details for its upcoming Annual Meeting of Shareholders. The webcast will provide shareholders with insights into the company's performance and future strategies. Further specifics about the meeting's agenda and participation were not disclosed in the announcement.
Read more →OMEROmeros Corporation Reports First Quarter 2026 Financial Results
Omeros Corporation has reported its financial results for the first quarter of 2026. The article provides insights into the company's performance but lacks detailed information on specific financial metrics or operational updates. Overall, the report appears to be a standard financial disclosure without significant developments.
Read more →OMEROmeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Omeros Corporation is set to announce its financial results for the first quarter on May 13, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will likely be provided during the announcement.
Read more →OMER▲ +7.2%on this news
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
Omeros Corporation announced that CMS has assigned a permanent J-code for YARTEMLEA, enhancing billing and reimbursement processes for patients. Effective July 1, 2026, this J-code will facilitate access to treatment for TA-TMA, a severe complication of hematopoietic stem cell transplantation. The initiative aims to reduce administrative burdens and improve patient care.
Read more →OMER▲ +14.4%on this news
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
Omeros Corporation reported strong financial results for Q4 and the year ending December 31, 2025, highlighted by the FDA approval of YARTEMLEA and a successful commercial launch. The company recognized significant net income and reduced its debt substantially. A partnership with Novo Nordisk is expected to enhance its pipeline and financial stability, despite a net loss for the year.
Read more →OMEROmeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Omeros Corporation announced it will release its financial results for Q4 and the full year of 2025 on March 31, 2026. A conference call will follow to discuss the results and recent developments. The company is known for its innovative therapeutics, including the FDA-approved YARTEMLEA for TA-TMA. Omeros is also advancing its pipeline with various clinical programs.
Read more →OMEROmeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Omeros Corporation announced its participation in the upcoming EBMT 2026 meeting, where it will host a session on advances in TA-TMA treatment. The session will be co-chaired by notable experts and feature discussions on novel targeted therapies. Omeros continues to develop innovative treatments, including its FDA-approved product YARTEMLEA for TA-TMA.
Read more →OMEROmeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
Omeros Corporation announced the successful completion of a primate study for its OncotoX-AML cancer therapeutic, targeting acute myeloid leukemia (AML). The study showed a significant reduction in myeloid progenitor cells and no adverse safety signals. Omeros plans to initiate IND-enabling studies to advance OncotoX-AML to clinical trials, aiming for a first-in-human trial by late 2027.
Read more →OMER▼ -6.8%on this news
Omeros Announces First Commercial Sales of YARTEMLEA®
Omeros Corporation has announced the first commercial sales of YARTEMLEA, the only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The drug is now being administered to both adult and pediatric patients, including those who previously failed other treatments. YARTEMLEA selectively inhibits MASP-2, a key enzyme in the complement pathway, and has received FDA approval. A marketing authorization application for the drug is also under review by the European Medicines Agency.
Read more →OMER▲ +5.5%on this news
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
Omeros Corporation has announced a new date for its conference call to discuss the FDA approval of YARTEMLEA, the first therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The call is scheduled for January 7, 2026, to accommodate investor schedules. YARTEMLEA is set for U.S. market launch on January 2, 2026.
Read more →OMEROmeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
Omeros Corporation has finalized an asset purchase and licensing agreement with Novo Nordisk for its clinical-stage MASP-3 inhibitor, zaltenibart. The agreement includes an upfront payment of $240 million and potential total payments of up to $2.1 billion. Zaltenibart targets complement-mediated diseases and is positioned as a promising treatment option for various rare disorders. Omeros retains rights to its related small-molecule programs.
Read more →OMER▲ +6.7%on this news
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
Omeros Corporation announced a registered direct offering to sell approximately $22 million of its common stock at a price of $4.10 per share. This offering, priced at a 14% premium to its previous closing price, is set to close on or about July 28, 2025. The proceeds from this sale are expected to enhance the company's ability to develop its therapeutics targeting immunologic disorders and other health conditions. The offering follows a registration statement filed with the SEC, ensuring regulatory compliance.
Read more →About Omeros Corporation
Headquarters201 ELLIOTT AVENUE WEST, SEATTLE, WA, 98119
BIOPHARMAWATCH ELITE PLUS
Trade the next OMER catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime